New imaging clues could sharpen brain tumor monitoring

NCT ID NCT07052877

Recruiting now Diagnosis Sponsor: Royal North Shore Hospital Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial explores whether a PSMA PET scan can detect changes in glioblastoma, an aggressive brain cancer, after treatment with bevacizumab. About 20 adults with IDH-wildtype glioblastoma will receive PSMA scans before and after bevacizumab therapy. The goal is to see if PSMA expression on the scan changes with treatment, which could offer a new way to monitor tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PSMA PET/CT scan (diagnostic imaging test)
What this could lead to: If successful, this could improve how glioblastoma is monitored, helping doctors see tumor changes more clearly and guide treatment decisions.
What could go wrong: This is a small early-stage study, and PSMA PET may not reliably reflect tumor response. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) glioblastoma glioma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA GLIOBLASTOMA MULTIFORME (GBM)

Contacts and locations

Locations

Royal North Shore Hospital
RECRUITING

Saint Leonards, New South Wales, 2065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.